Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical <scp>ASCVD</scp> Study

20260 citationsJournal Article

Authors

Michael G. Nanna · Yale University

Carlos Mena‐Hurtado · Yale University

Victoria Divino · Novo Nordisk (United States)

Zhenxiang Zhao · Novo Nordisk (United States)

Yan Chen · Analysis Group (United States)

Joanna Boland · Analysis Group (United States)

Jinlin Song ·

Abstract

Semaglutide 2.4 mg was associated with a significantly reduced risk of MACE and other obesity-related outcomes, extending prior evidence of benefits to a broader clinical ASCVD population.

Topics & Keywords

Diabetes Treatment and Management Lipoproteins and Cardiovascular Health Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.70686

Field-Weighted Citation Impact: 0.00